Embera NeuroTherapeutics' EMB-001 well tolerated in phase Ib cocaine interaction study May 9, 2017 No Comments
SRI International receives FDA clearance to evaluate novel oral formulation of Zn-DTPA April 3, 2017 No Comments
BARDA elects not to exercise options for AEOL-10150 development for ARS and DEARE March 28, 2017 No Comments
Opiant receives FDA feedback on development of OPNT-002 for alcohol use disorder March 2, 2017 No Comments
Aeolus Pharmaceuticals starts phase I study of new formulation of AEOL-10150 Feb. 23, 2017 No Comments
RSS